EyeBio is a clinical-stage biotech company specializing in ophthalmology. The company's primary mission is to develop innovative therapies to protect, restore, and improve vision for individuals suffering from eye diseases. EyeBio operates in the healthcare sector, specifically in the market for eye disease treatments.

The company's business model revolves around the research, development, and commercialization of advanced therapies for eye diseases. EyeBio's revenue generation strategy is likely to be based on the sales of these therapies once they have been approved for use.

EyeBio was co-founded by Dr. David Guyer and Dr. Anthony P. Adamis, who were instrumental in introducing the first anti-vascular endothelial growth factor (anti-VEGF) therapy for patients with age-related macular degeneration (AMD). This therapy inhibits the growth of new blood vessels in the eye, which can lead to vision loss in AMD patients.

EyeBio's lead asset is Restoret, a clinical-stage therapy targeting the Wnt pathway to treat retinal diseases. The Wnt pathway is a group of signal pathways made of proteins that pass signals into a cell through cell surface receptors.

The company is backed by a team of investors from leading healthcare fund managers, including SV Health Investors, Samsara BioCapital, Jeito Capital, MRL Ventures, Bain Capital, Omega Funds, and Vertex Ventures.

EyeBio's leadership team and board of directors have a proven track record in developing groundbreaking ophthalmology therapies, making them a strong contender in the eye disease treatment market.

Keywords: EyeBio, Ophthalmology, Biotech, Eye Diseases, Therapies, Clinical-Stage, Anti-VEGF, Restoret, Wnt Pathway, Healthcare Investors.